4.6 Article

Microscopic colitis: Current status, present and future challenges Statements of the European Microscopic Colitis Group

期刊

JOURNAL OF CROHNS & COLITIS
卷 6, 期 9, 页码 932-945

出版社

OXFORD UNIV PRESS
DOI: 10.1016/j.crohns.2012.05.014

关键词

Microscopic colitis; Collagenous colitis; Lymphocytic colitis; Budesonide

资金

  1. Tillots Pharma
  2. Falk Pharma
  3. Tillotts Pharma
  4. Ferring
  5. MSD
  6. Astra-Zeneca
  7. Falk Foundation, Germany
  8. MEDA, Sweden

向作者/读者索取更多资源

Microscopic colitis (MC) is an inflammatory bowel disease presenting with chronic, non-bloody watery diarrhoea and few or no endoscopic abnormalities. The histological examination reveals mainly two subtypes of MC, lymphocytic or collagenous colitis. Despite the fact that the incidence in MC has been rising over the last decades, research has been sparse and our knowledge about MC remains limited. Specialists in the field have initiated the European Microscopic Colitis Group (EMCG) with the primary goal to create awareness on MC. The EMCG is furthermore a forum with the intention to promote clinical and basic research. In this article statements and comments are given that all members of the EMCG have considered being of importance for a better understanding of MC. The paper focuses on the newest updates in epidemiology, symptoms and diagnostic criteria, pathophysiology and highlights some unsolved problems. Moreover, a new treatment algorithm is proposed on the basis of new evidence from well-designed, randomized control trials. (C) 2012 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据